Landgraf, Wolfgang http://orcid.org/0000-0001-5321-7164
Owens, David R. http://orcid.org/0000-0003-1002-1238
Frier, Brian M. http://orcid.org/0000-0002-9590-9473
Bolli, Geremia B. http://orcid.org/0000-0003-4966-4003
Funding for this research was provided by:
Sanofi
Article History
Received: 7 May 2024
Accepted: 3 June 2024
First Online: 15 June 2024
Declarations
:
: Wolfgang Landgraf is an employee of Sanofi, Germany, and Sanofi shareholder. Brian M. Frier has served on an advisory panel for Zucara Therapeutics. David R. Owens has received honoraria for lecturing and consulting from Boehringer Ingelheim, Eli Lilly, Roche Diagnostics, Sanofi, and Takeda. Geremia B. Bolli is a consultant for Eli Lilly and Sanofi, has received research support from Sanofi and is on the speakers’ bureau for Eli Lilly, Menarini, and Sanofi.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors. The underlying EDITION studies received ethics approval for all study sites, were conducted in accordance with the Declaration of Helsinki, and written informed consent was collected from all participants.